Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385073487> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W4385073487 endingPage "4110" @default.
- W4385073487 startingPage "4105" @default.
- W4385073487 abstract "The purpose of this study was to report the real-world treatment outcomes using a treat-and-extend intravitreal bevacizumab protocol in cystoid macular oedema (CMO) secondary to central retinal vein occlusion (CRVO).We conducted a retrospective case series of consecutive adult patients with CMO secondary to CRVO who presented between 1st January 2019 and 31st December 2021. All included patients were treated with bevacizumab using a treat-and-extend protocol, were followed up for a minimum of 6 months and had a clinical examination including best-corrected visual acuity (BCVA) and optical coherence tomography (OCT) at every visit. The primary outcome measure was mean change in BCVA.Thirty-three eyes of 33 patients were included in the study. The mean change in BCVA from baseline was + 24.5 (Median 18, SD 21.5) letters, with a mean follow-up duration of 18.5 (SD 8.9) months. The mean number of injections was 9.5 (SD 1.9) in year 1 and 7.8 (SD 2.8) in year 2. 87.9% of patients were still requiring active treatment, with a maximum interval achieved of 4-weekly in 18.2%, 6-weekly in 42.4%, 8-weekly in 6.1%, 10-weekly in 15.2%, and 12-weekly in 6.1%. The mean maximum interval achieved of those requiring ongoing treatment was 6.8 (SD 2.4) weeks. Multiple regression analyses showed that a higher baseline BCVA was negatively associated with mean visual acuity gain (P < 0.001) and positively associated with final BCVA (P < 0.001).The use of intravitreal bevacizumab in a treat-and-extend regimen is effective in treating CMO secondary to CRVO, in a real-world setting." @default.
- W4385073487 created "2023-07-23" @default.
- W4385073487 creator A5012915418 @default.
- W4385073487 creator A5048550215 @default.
- W4385073487 creator A5065682639 @default.
- W4385073487 creator A5072294072 @default.
- W4385073487 date "2023-07-22" @default.
- W4385073487 modified "2023-10-17" @default.
- W4385073487 title "Real-world outcomes of intravitreal bevacizumab treat-and-extend for cystoid macular oedema secondary to central retinal vein occlusion" @default.
- W4385073487 cites W1971399814 @default.
- W4385073487 cites W1973608834 @default.
- W4385073487 cites W1976154023 @default.
- W4385073487 cites W1978704499 @default.
- W4385073487 cites W2089494988 @default.
- W4385073487 cites W2139351222 @default.
- W4385073487 cites W2144771657 @default.
- W4385073487 cites W2153879487 @default.
- W4385073487 cites W2172223254 @default.
- W4385073487 cites W2285674438 @default.
- W4385073487 cites W2612836720 @default.
- W4385073487 cites W2737483168 @default.
- W4385073487 cites W2793346692 @default.
- W4385073487 cites W2931710213 @default.
- W4385073487 cites W2940118684 @default.
- W4385073487 cites W2971306116 @default.
- W4385073487 cites W3042406417 @default.
- W4385073487 cites W3092983131 @default.
- W4385073487 cites W3105186992 @default.
- W4385073487 cites W3126975289 @default.
- W4385073487 cites W3131125541 @default.
- W4385073487 cites W3183453989 @default.
- W4385073487 cites W4220950679 @default.
- W4385073487 doi "https://doi.org/10.1007/s10792-023-02811-1" @default.
- W4385073487 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37481673" @default.
- W4385073487 hasPublicationYear "2023" @default.
- W4385073487 type Work @default.
- W4385073487 citedByCount "1" @default.
- W4385073487 countsByYear W43850734872023 @default.
- W4385073487 crossrefType "journal-article" @default.
- W4385073487 hasAuthorship W4385073487A5012915418 @default.
- W4385073487 hasAuthorship W4385073487A5048550215 @default.
- W4385073487 hasAuthorship W4385073487A5065682639 @default.
- W4385073487 hasAuthorship W4385073487A5072294072 @default.
- W4385073487 hasBestOaLocation W43850734871 @default.
- W4385073487 hasConcept C118487528 @default.
- W4385073487 hasConcept C126322002 @default.
- W4385073487 hasConcept C141071460 @default.
- W4385073487 hasConcept C167135981 @default.
- W4385073487 hasConcept C2776694085 @default.
- W4385073487 hasConcept C2777802072 @default.
- W4385073487 hasConcept C2778257484 @default.
- W4385073487 hasConcept C2778844676 @default.
- W4385073487 hasConcept C2780347916 @default.
- W4385073487 hasConcept C44249647 @default.
- W4385073487 hasConcept C71924100 @default.
- W4385073487 hasConceptScore W4385073487C118487528 @default.
- W4385073487 hasConceptScore W4385073487C126322002 @default.
- W4385073487 hasConceptScore W4385073487C141071460 @default.
- W4385073487 hasConceptScore W4385073487C167135981 @default.
- W4385073487 hasConceptScore W4385073487C2776694085 @default.
- W4385073487 hasConceptScore W4385073487C2777802072 @default.
- W4385073487 hasConceptScore W4385073487C2778257484 @default.
- W4385073487 hasConceptScore W4385073487C2778844676 @default.
- W4385073487 hasConceptScore W4385073487C2780347916 @default.
- W4385073487 hasConceptScore W4385073487C44249647 @default.
- W4385073487 hasConceptScore W4385073487C71924100 @default.
- W4385073487 hasFunder F4320313911 @default.
- W4385073487 hasIssue "11" @default.
- W4385073487 hasLocation W43850734871 @default.
- W4385073487 hasLocation W43850734872 @default.
- W4385073487 hasOpenAccess W4385073487 @default.
- W4385073487 hasPrimaryLocation W43850734871 @default.
- W4385073487 hasRelatedWork W1668980245 @default.
- W4385073487 hasRelatedWork W2027199077 @default.
- W4385073487 hasRelatedWork W2036716768 @default.
- W4385073487 hasRelatedWork W2041448642 @default.
- W4385073487 hasRelatedWork W2069287335 @default.
- W4385073487 hasRelatedWork W2294668099 @default.
- W4385073487 hasRelatedWork W2348628890 @default.
- W4385073487 hasRelatedWork W2368356977 @default.
- W4385073487 hasRelatedWork W3169518082 @default.
- W4385073487 hasRelatedWork W4238335834 @default.
- W4385073487 hasVolume "43" @default.
- W4385073487 isParatext "false" @default.
- W4385073487 isRetracted "false" @default.
- W4385073487 workType "article" @default.